Volume 6.25 | Jun 30

Hematopoiesis News 6.25 June 30, 2015
Hematopoiesis News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  HN on Twitter
The Transcription Factor Foxm1 Is Essential for the Quiescence and Maintenance of Hematopoietic Stem Cells
The authors found that Foxm1 was essential for maintenance of the quiescence and self-renewal capacity of hematopoietic stem cells (HSCs) in vivo in mice. Reducing expression of FOXM1 also decreased the quiescence of human CD34+ HSCs and progenitor cells, and its downregulation was associated with a subset of myelodysplastic syndrome. [Nat Immunol] Abstract
Only One of These Antibodies Will Work for Your Cell Analysis. We Take the Guesswork Out of Finding the Right
PUBLICATIONS (Ranked by impact factor of the journal)
Chemically Modified Guide RNAs Enhance CRISPR-Cas Genome Editing in Human Primary Cells
The authors report that chemical alterations to synthesized single guide RNAs enhanced genome editing efficiency in human primary T cells and CD34+ hematopoietic stem and progenitor cells. [Nat Biotechnol] Abstract

Aspp1 Preserves Hematopoietic Stem Cell Pool Integrity and Prevents Malignant Transformation
Researchers showed that Aspp1 coordinated with p53 to maintain the genomic integrity of the hematopoietic stem cell (HSC) pool. Aspp1 is preferentially expressed in HSCs and restricts HSC pool size by attenuating self-renewal under steady-state conditions. [Cell Stem Cell] Abstract | Graphical Abstract

Functionally Distinct Subsets of Lineage-Biased Multipotent Progenitors Control Blood Production in Normal and Regenerative Conditions
Scientists found that all multipotent progenitors are produced in parallel by hematopoietic stem cells, but with different kinetics and at variable levels depending on hematopoietic demands. [Cell Stem Cell] Abstract

Plerixafor+G-CSF-Mobilized CD34+ Cells Represent an Optimal Graft Source for Thalassemia Gene Therapy
CD34+ cells from 31 thalassemic patients mobilized with Hydroxyurea+G-CSF, G-CSF, Plerixafor or Plerixafor+G-CSF were transduced with the TNS9.3.55 β-globin lentivector and compared for transducibility and globin expression in vitro, as well as engraftment potential in a xenogeneic model after partial myeloablation. [Blood] Abstract

FoxO1-Dependent Induction of Acute Myeloid Leukemia by Osteoblasts in Mice
Scientists showed that Notch1 is the receptor mediating the leukemogenic properties of osteoblast-activated β-catenin in hematopoietic stem cells. [Leukemia] Abstract

EphA2 Is a Therapy Target in EphA2-Positive Leukemias but Is Not Essential for Normal Hematopoiesis or Leukemia
Investigators explored the role of EphA2 in hematopoiesis by analyzing wild type and EphA2 knockout mice. Mature, differentiated cells, progenitors and hematopoietic stem cells derived from knockout and control mice were analyzed and no significant abnormality was detected. These studies showed that EphA2 does not have an obligatory role in normal hematopoiesis. [PLoS One] Full Article

Retrovirus-Mediated Expression of E2A-PBX1 Blocks Lymphoid Fate but Permits Retention of Myeloid Potential in Early Hematopoietic Progenitors
Researchers elucidated the hematopoietic consequences of forced E2A-PBX1 expression in primary murine hematopoietic progenitors. They showed that introducing E2A-PBX1 into multipotent progenitors permitted the retention of myeloid potential but imposed a dense barrier to lymphoid development prior to the common lymphoid progenitor stage [PLoS One] Full Article


Outcomes of Patients with Therapy-Related AML/Myelodysplastic Syndrome (T-AML/MDS) following Hematopoietic Cell Transplantation
The authors studied outcomes of 65 consecutive patients with therapy-related AML/myelodyplastic (t-AML/MDS) syndrome who underwent allogeneic hematopoietic cell transplantation. Patients with t-AML/MDS had poor overall survival (OS). Unrelated donor is a significant risk factor for both higher NRM and decreased OS. [Bone Marrow Transplant] Abstract

Second Allogeneic Hematopoietic Stem Cell Transplantation in Children with Severe Aplastic Anemia
The outcome of 55 children with severe aplastic anemia who received a second hematopoietic stem cell transplantation was retrospectively analyzed using the registration data of the Japanese Society for Hematopoietic Cell Transplantation. The 5-year overall survival and failure-free survival after the second transplantation were 82.9% and 81.2%, respectively. [Bone Marrow Transplant] Abstract

Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) Overcomes Poor Prognosis of Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC)
Researchers analyzed transplant outcomes among 147 patients with AML-MRC or AML-NOS who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) in a single institution. There were no significant differences in the 2-year overall survival, cumulative incidence of relapse, and non-relapse mortality between the two groups. [Leuk Lymphoma] Abstract

Get More of the Cells You Need with StemSpan™ Megakaryocyte Expansion Supplement and StemSpan™ SFEM
Immuno-Metabolism and Adipose Tissue: The Key Role of Hematopoietic Stem Cells
The authors discuss the alterations of hematopoietic process described in metabolic diseases and focus on the emerging data concerning hematopoietic stem cells present in white adipose tissue. [Biochimie] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.
Celator® Pharmaceuticals Announces Positive Induction Response Results from Phase III Study of CPX-351 in Patients with High-Risk (Secondary) Acute Myeloid Leukemia
Celator Pharmaceuticals, Inc. announced final induction response rate results in the Phase III study comparing CPX-351 liposome injection to the standard of care regimen in patients with untreated high-risk (secondary) acute myeloid leukemia. [Celator Pharmaceuticals, Inc.] Press Release

Ontario Invests in Better Health and Economic Opportunity through Support for Ontario Institute for Regenerative Medicine
A new $25 million commitment positions Ontario to be an early adopter of new treatments and technologies emerging from research and commercial developments in regenerative medicine. [Ontario Institute for Regenerative Medicine] Press Release

STEMCELL Technologies Launches Innovative Products to Support CAR T Cell Research
STEMCELL Technologies Inc. announced the launch of ImmunoCult™ Human T Cell Activator reagents and ImmunoCult™-XF T Cell Expansion Medium to support T cell researchers in their goal to develop CAR T cell immunotherapeutics. The products provide significant benefits compared to existing technologies. [STEMCELL Technologies Inc.] Press Release

From our sponsor:
Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Frontiers in Basic Immunology 2015
October 8-9, 2015
Bethesda, Maryland, United States

NEW Nordic Life Sciences Days 2015
September 9-10, 2015
Stockholm, Sweden

Visit our events page to see a complete list of events in the hematopoiesis community.
NEW Clinical Research Coordinator – Chronic Lymphocytic Leukemia (Fred Hutchinson Cancer Research Center)

Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Postdoctoral Position – Hematopoietic Stem Cell Transplantation (St. Jude Children’s Research Hospital)

Postdoctoral Position – Hematopoietic Stem Cell and Hematologic Malignancy (University of Kentucky College of Medicine)

Postdoctoral Fellow – Hematopoietic Stem Cell Biology (Harvard Medical School)

Postdoctoral Fellow – Immune Reconstitution in Hematopoietic Stem Cell Transplantation (Stanford University)

Postdoctoral Fellow – Immune Tolerance (Stanford University)

Postdoctoral Position – Epigenetic Regulation of Hematopoiesis and Leukemia (Karolinska Institute)

Postdoctoral Fellow – Leukemia, Stem Cells and Development (Josep Carreras Leukemia Research Institute)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Hematopoiesis News: Archives | Events | Contact Us